Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec;9(2):82-9.
doi: 10.1016/j.autrev.2009.08.007. Epub 2009 Aug 27.

Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis

Thomas Dörner  1 , David Isenberg, David Jayne, Heinz Wiendl, Detlef Zillikens, Gerd Burmester; International Roundtable on B cells as Therapeutic Target for Intervention
Collaborators, Affiliations
Review

Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis

Thomas Dörner et al. Autoimmun Rev. 2009 Dec.

Abstract

Since the approval of the chimeric anti-CD20 antibody rituximab for the treatment of adults with severe-to-moderate rheumatoid arthritis after an inadequate response to TNF blockade, B-cell depletion therapy has been used for the treatment of a broad range of refractory autoimmune disorders. Based on current experiences and a literature search, a systematic review and evaluation of the current status of B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis, including rheumatic, nephrologic, dermatologic and neurologic autoimmune entities, was performed by an international group of experts based at several academic centres. Although important questions remain about the value and place of B-cell depletion in autoimmune diseases other than RA, preliminary data indicate the value of this therapeutic approach in otherwise refractory patients. However, given the lack of robust data from large randomised controlled trials, anti-CD20 therapy should be considered on an individual basis in otherwise refractory patients and its use based on a risk/benefit net calculation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

LinkOut - more resources